Kostas Biliouris
Stock Analyst at Oppenheimer
(2.05)
# 3,324
Out of 4,690 analysts
436
Total ratings
42.3%
Success rate
0.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterated: Buy | $9 | $2.29 | +293.01% | 4 | Aug 14, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Maintained: Buy | $55.64 | $12.11 | +359.44% | 3 | Aug 14, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $9 | $2.80 | +221.43% | 2 | Aug 14, 2026 | |
| LEGN Legend Biotech | Downgraded: Hold | $75 → $40 | $19.88 | +101.21% | 60 | Aug 12, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Buy | $37 → $35 | $20.86 | +67.79% | 38 | Aug 6, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintained: Buy | $500 → $350 | $237.10 | +47.62% | 41 | Jul 31, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.61 | +204.71% | 19 | Jul 24, 2026 | |
| NRIX Nurix Therapeutics | Maintained: Buy | $28 | $26.21 | +6.83% | 2 | Jul 10, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $3.69 | +171.00% | 2 | Jun 17, 2026 | |
| DSGN Design Therapeutics | Reiterated: Buy | $21 | $15.11 | +38.98% | 4 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $7.78 | +157.07% | 21 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $7.00 | +228.57% | 4 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $13.23 | +277.93% | 3 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.08 | +387.01% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $12.91 | +70.41% | 18 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $64.67 | - | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $61.05 | - | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.86 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.87 | - | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $76.60 | - | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $29.32 | - | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.6997 | - | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.07 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.42 | - | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.67 | - | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.19 | - | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $57.72 | +29.94% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.11 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $280.49 | n/a | 1 | Jun 16, 2022 |
ProQR Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $2.29
Upside: +293.01%
Satellos Bioscience Inc.
Aug 14, 2026
Maintained: Buy
Price Target: $55.64
Current: $12.11
Upside: +359.44%
Ovid Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $2.80
Upside: +221.43%
Legend Biotech
Aug 12, 2026
Downgraded: Hold
Price Target: $75 → $40
Current: $19.88
Upside: +101.21%
Sarepta Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $37 → $35
Current: $20.86
Upside: +67.79%
Alnylam Pharmaceuticals
Jul 31, 2026
Maintained: Buy
Price Target: $500 → $350
Current: $237.10
Upside: +47.62%
Prime Medicine
Jul 24, 2026
Reiterated: Buy
Price Target: $11
Current: $3.61
Upside: +204.71%
Nurix Therapeutics
Jul 10, 2026
Maintained: Buy
Price Target: $28
Current: $26.21
Upside: +6.83%
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $10
Current: $3.69
Upside: +171.00%
Design Therapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $15.11
Upside: +38.98%
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.78
Upside: +157.07%
Jun 3, 2026
Reiterated: Buy
Price Target: $23
Current: $7.00
Upside: +228.57%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $13.23
Upside: +277.93%
Mar 31, 2026
Reiterated: Buy
Price Target: $15
Current: $3.08
Upside: +387.01%
Mar 13, 2026
Reiterated: Buy
Price Target: $22
Current: $12.91
Upside: +70.41%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $64.67
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $61.05
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $3.86
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $12.87
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $76.60
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $29.32
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.6997
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $25.07
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $13.42
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $14.67
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.19
Upside: -
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $57.72
Upside: +29.94%
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.11
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $280.49
Upside: n/a